TD Cowen Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1000
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tyler Van Buren has maintained an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $900 to $1000.

December 06, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Tyler Van Buren reaffirmed an Outperform rating on Regeneron Pharmaceuticals and raised the price target to $1000, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100